title: Recurrent bone marrow aplasia secondary to nilotinib in a patient with chronic myeloid leukemia: a case report.
abstract: Nilotinib is a potent tyrosine kinase inhibitor of breakpoint cluster region-abelson (BCR-ABL), which has been approved as front-line therapy for newly diagnosed chronic myeloid leukemia in chronic phase and as second-line therapy after imatinib failure in chronic or accelerated phase chronic myeloid leukemia. Tyrosine kinase inhibitors have been associated with myelosuppression and grade 3 or grade 4 cytopenias are not uncommon in chronic myeloid leukemia patients treated with these drugs. There are a few reports of imatinib-associated bone marrow aplasia, but to our knowledge only one reported case of bone marrow aplasia associated with nilotinib. Herein, we report a 49-year-old male patient with chronic phase chronic myeloid leukemia, who developed severe bone marrow aplasia due to nilotinib. Possible mechanisms for this significant adverse drug reaction are discussed along with a review of literature.
authors.affiliation: Department of Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE 68198-7680, USA.
authors.forename: Prathima
authors.initials: P
authors.lastname: Prodduturi
authors.forename: Anamarija M
authors.initials: AM
authors.lastname: Perry
authors.forename: Patricia
authors.initials: P
authors.lastname: Aoun
authors.forename: Dennis D
authors.initials: DD
authors.lastname: Weisenburger
authors.forename: Mojtaba
authors.initials: M
authors.lastname: Akhtari
mesh_terms: D001855:Bone Marrow Diseases / Q000139:chemically induced*; D006801:Humans; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use*
chemical_list: D011743:Pyrimidines; C498826:nilotinib